Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

BioSante third quarter net loss increases to $12.7 million

BioSante Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2011 and provided an update on the Company's pipeline.

9 Nov 2011

Antares Pharma third quarter total revenues increase 26% to $3.9M

Antares Pharma, Inc. today reported financial and operating results for the third quarter ended September 30, 2011.

8 Nov 2011

Bike riding cuts off blood flow to men's genitals

Is it just an urban myth, or can long-term bike riding cause sexual dysfunction in men? Previous studies have not shed much light on the question, says Dr. Craig Niederberger, professor and head of urology at the University of Illinois at Chicago College of Medicine, because they have not shown whether bike riding actually cuts off blood flow to men's genitals.

7 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Studies find less vitamin D intake among menopausal women

A healthy diet is especially important during the menopause - a period in which the risk of suffering from health problems increases. Various studies analyse the diet of peri- and postmenopausal women in Spain alongside the troubles that come with this transition. The results show that all of those groups studied have a deficient intake of vitamin D.

21 Oct 2011

USPTO issues patent to Rexahn's new anti-cancer arylisoquinolinamine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."

13 Oct 2011

DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study

BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.

11 Oct 2011

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.

29 Sep 2011

Role of email advice in patients with sexual problems

More than two-thirds of men who contacted an email advice service run by a leading sexual advice charity had erection problems, which were frequently linked to loss of sex drive, according to research in the October issue of IJCP, the International Journal of Clinical Practice.

23 Sep 2011

Palatin's fourth quarter net loss decreases to $3.3 million

Palatin Technologies, Inc., a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.

22 Sep 2011

Impotence after prostate cancer treatment

According to researchers patients undergoing treatment for prostate cancer could be at a risk of impotence. According to the new study, published in the Journal of the American Medical Association there may be a formula to help gauge those risks for three common types of treatment, including surgery and radiation.

21 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

BioSante Pharmaceuticals, Inc., today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study.

12 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Today, Bayer Inc. announced the Health Canada approval of STAXYN, the first orally disintegrating tablet for the treatment of erectile dysfunction (ED) that lasts up to eight hours.

29 Aug 2011

Online health records, medical devices face IT security risks

Meanwhile, iWatch News reports on how the health information sector seems especially fond of lobbying's "revolving door."

22 Aug 2011

New source for sexual problems in men – buddies!

Social researchers have found that there may be a new source for sexual problems among middle-aged and older men and it could be the relationships between their female partners and the men's closest friends.

12 Aug 2011

Researchers identify new source for sexual problems in middle-aged, older men

Researchers have found a potential new source for sexual problems among middle-aged and older men: the relationships between their female partners and the men's closest friends.

9 Aug 2011

EPO issues European patent for Rexahn's neurotherapeutic compositions

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."

9 Aug 2011

Even minor weight loss can improve men’s sex lives: Study

The team of Australian researchers placed 31 obese men with type 2 diabetes on either a meal replacement-based low-calorie diet or a low-fat, high-protein, reduced-carbohydrate diet meant to decrease calorie intake by 600 calories a day. A modest weight loss of 5 percent led to an easing of erectile dysfunction and improved sexual desire within eight weeks, and these improvements continued for 12 months, according to the study published Aug. 5 in The Journal of Sexual Medicine. Problems with urinary tract function also improved, the team added.

8 Aug 2011